A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Recruiting

Phase 2

Phase 3

Fianlimab & CemiplimabA Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT05800015

Conditions

Non-small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

fianlimab

cemiplimab

Pemetrexed

Paclitaxel

Carboplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2025-05-13.